By Annette Williams, R.Ph, Vice President and Global Head of Lifecycle Safety, IQVIA, and Barry Mulchrone, Senior Director and Head of Pharmacovigilance Oversight and Analytics
As with many areas of the pharmaceutical industry, COVID-19 created significant disruption for pharmacovigilance (PV) activities, including post-marketing surveillance. The rapidly growing volume of data along with shifting regulatory and consumer trends due to the pandemic, forced leaders to rethink their typical safety data management processes and PV technology, in order to bring unprecedented levels of scalability, reliability and agility to their workflow.
IQVIA's Lifecycle Safety and Pharmacovigilance team has been on the front lines of this pandemic from the start, providing support to several customers conducting research into COVID medicines and vaccines, as well as providing global PV support. Discover the challenges to maintaining PV standards and experienced the opportunities to reimagine PV strategies and accelerate the implementation of automation and process changes.